| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-752 | |
| Phytochemical name or plant extracts | Cleistenolide | |
| PMID | 31362371 | |
| Literature evidence | Our findings demonstrate the potential applicability of C. kirkii as a source of antimalarial and anticancer agents. | |
| IUPAC name | [(2R)-2-acetyloxy-2-[(2S,3R)-3-acetyloxy-6-oxo-2,3-dihydropyran-2-yl]ethyl] benzoate | |
| Phytochemicals’ class or type of plant extracts | Heptenolides | |
| Source of phytochemicals or plant Extracts | Cleistochlamys kirkii | |
| Geographical availability | Malawi, Mozambique, Tanzania, Zambia, Zimbabwe | |
| Plant parts | Root | |
| Other cancers | Breast cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | 30.7 µM against MDA-MB-231 | |
| Potency | This indicates the potential applicability of C. kirkii as a source of antimalarial, and even more likely of anticancer agents. | |
| Cell line/ mice model | MDA-MB-231 | |
| Additional information | Heptenolide 13 isolated from the stem ethanolic extract along with flavonoids 2–4, 7 and heptenolide 12 also exhibited potent antiplasmodial activity | |
| PubChem ID | 46187371 | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:72604-1 | |
| Safety | NA |